slides · global inventory
Show Traction
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 11,828
Current window 7,231-7,260
Pages 395
Rows per page 30
Slide function
7,231-7,260 of 11,828
12
Includes PK/PD correlation, blood IRAK4 levels, skin exposure, and skin lesion IRAK4 reduction data.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
14
Data compares 'All HS Patients' vs 'Moderate to Severe' subgroups across four metrics over 42 days.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
16
Data presented as mean +/- S.E. of mean; N=7 patients.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
19
The slide outlines the status of a partnership with Sanofi and clinical trial timelines.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · DesireLoop · Logic Chain1 hit
23
Includes PK/PD data and efficacy metrics in multiple T-cell lymphoma models.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
24
Includes box plots for gene expression and a tumor volume growth curve over time.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
29
The table tracks clinical trial outcomes (PR: Partial Response, SD: Stable Disease, PD: Progressive Disease) for a drug candidate.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
30
Includes both tabular summary of dose-level degradation and visual histology/bar chart evidence of tumor reduction.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
31
Includes longitudinal line charts for blood mRNA levels and a bar chart/enrichment plot for tumor response.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
32
The slide uses a split-layout: left side for clinical data results, right side for strategic opportunity/implications.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
36
Comparison of protein levels and tumor volume over time across multiple dosing regimens.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
38
The slide uses a biological mechanism diagram on the left and clinical data (table and line chart) on the right to validate the drug's mechanism of action.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
39
The chart is a swimmer plot, a standard tool in oncology clinical trials to visualize duration of response.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
40
Clinical trial safety reporting slide.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
41
The slide uses a split-layout comparing technical mechanism/data (left) with strategic opportunity (right).Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
46
Includes both a summary table of response categories and a swimmer plot for treatment duration.Kymera | Investor Presentation Deck | 46 slides · Kymera Therapeutics
Pitch deck Investor relations Beat · Action1 hit
14
The slide categorizes the order book into Electric Vehicles (buses and trucks) and LionEnergy (charging stations), with client logos displayed for each segment.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
15
Includes images of both a Bolt truck and a fleet of Lion Electric school buses.Lion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
17
Lion Electric | Investor Presentation Deck | 31 slidesLion Electric | Investor Presentation Deck | 31 slides · Lion Electric
Pitch deck Investor relations Beat · FinancialsLoop · Quick Win Big Bet1 hit
12
The slide uses a matrix-like structure to categorize content types against volume metrics and historical performance indicators.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
14
The slide uses a three-part structure to explain the flywheel of content investment, acquisition, and revenue growth.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
16
The slide highlights the company's inorganic growth strategy through various studio and library acquisitions.Lionsgate | SPAC Presentation Deck | 35 slides · Lionsgate
Pitch deck Investment bank 1 hit
08
The slide uses a three-column layout to categorize achievements by strategic pillar.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
14
The table compares two distinct clinical trials (ColoFuture and eAArly DETECT) across key performance metrics.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
13
Notes at bottom define FPFV and LPO.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
08
The chart uses hazard ratio as a metric for efficacy in an iPSC model derived from ALS patients.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
Includes study design parameters (NST002) and key clinical outcomes.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The slide highlights clinical trial safety data for PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Before After1 hit
17
The slide highlights a 37.4% reduction in disease progression with statistical significance (p=0.03) in the per-protocol population, while noting a 29% reduction in the ITT analysis.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Before After1 hit
19
The chart visualizes the reduction in points lost, highlighting a 3.22 point difference (p=0.03).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit